1993 Sir Henry Wellcome Medal and Prize recipient. The rise and fall of mefloquine as an antimalarial drug in South East Asia.
Mefloquine is an antimalarial drug developed by the U.S. Army Antimalarial Drug Program in conjunction with the World Health Organization and Hoffmann-La Roche to address the problem of chloroquine-resistant falciparum malaria encountered during the Vietnam War. Despite the expenditure of millions of dollars over a 20-year period, it is unlikely that mefloquine will ever be used for U.S. soldiers deployed to South East Asia. Although mefloquine met the specifications set by its developers, its usefulness is now limited by the rapid evolution of drug resistance following its release to the civilian population. Drug development for particular military needs was compromised by a rapid biological response from the parasite and commercial concerns. In an era of shrinking military budgets, military drug development programs will by necessity be more resource constrained, thus yielding fewer new drugs per decade. In the short-term, emphasis should be directed toward adapting available antimicrobial drugs for antimalarial purposes.
Shanks
G D
GD
Australian Army Malaria Research Unit, PSC 280, APO AP 96554.
D000818:Animals; D000962:Antimalarials / Q000266:history* / Q000494:pharmacology / Q000627:therapeutic use; D001210:Asia, Southeastern; D001363:Awards and Prizes; D004351:Drug Resistance; D049673:History, 20th Century; D006801:Humans; D008288:Malaria / Q000188:drug therapy / Q000266:history* / Q000517:prevention & control; D015767:Mefloquine / Q000266:history* / Q000494:pharmacology / Q000627:therapeutic use; D010963:Plasmodium falciparum / Q000187:drug effects
D000962:Antimalarials; D015767:Mefloquine